Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Phathom Pharmaceuticals Q3 Adj. EPS $(0.15), Sales $49.504M Beat $46.993M Estimate

Author: Benzinga Newsdesk | October 30, 2025 06:21am
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.55) by 72.48 percent. This is a 85.71 percent increase over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $49.504 million which beat the analyst consensus estimate of $46.993 million by 5.34 percent. This is a 202.74 percent increase over sales of $16.352 million the same period last year.

Posted In: PHAT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist